^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TB-403

    i
    Other names: TB-403, R7334, RG 7334, RG7334, RO5323441, TB 403, R-7334, RO-5323441, αPlGF, THR-317
    Associations

    News

    Trials
    Company:
    BioInvent, Oxurion
    Drug class:
    PlGF inhibitor
    Associations

    News

    Trials
    over3years
    A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. (PubMed, Clin Cancer Res)
    TB-403 was safe and well tolerated at all dose levels. No MTD was reached. The results look encouraging and therefore warrant further evaluation of efficacy in pediatric subjects with MB.
    P1 data • Journal
    |
    NRP1 (Neuropilin 1)
    |
    NRP1 elevation
    |
    temozolomide • etoposide IV • TB-403
    almost6years
    Genetic Variants in the 3'UTR of BRCA1 and BRCA2 Genes and their Putative Effects on the microRNA Mechanism in Hereditary Breast and Ovarian Cancer. (PubMed, Diagnostics (Basel))
    We detected nine polymorphisms in 3'UTR, namely: four in BRCA1 (rs3092995 (C/G), rs8176318 (C/T), rs111791349 (G/A), and rs12516 (C/T)) and five in BRCA2 (rs15869 (A/C), rs7334543 (A/G), rs1157836 (A/G), and rs75353978 (TT/del TT))...The presence/absence of these polymorphisms may influence the loss/creation of miRNA binding sites, such as hsa-miR-1248 in BRCA1 3'UTR or the hsa-miR-548 family binding site in BRCA2. Our results add new evidence of miRNA participation in the pathogenesis of HBOC.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    TB-403